APL Healthcare’s Unit-IV classified as VAI by the USFDA
This inspection is now closed
This inspection is now closed
The Japan Patent Office is considered one of the world's most rigorous and meticulous in its review process
The FDA classified LifeVac as a Class II medical device
The trial met its primary endpoint, with patients receiving povetacicept achieving a 52.0% reduction in UPCR at Week 36
The approval comes after a systematic review of published literature
Phase I EPRAD study of DT-9081 demonstrated a favorable safety profile
The Hydrus Microstent stands out as the first and only MIGS device backed by five-year clinical outcomes
Giredestrant shows promise despite missing primary goal
The study hit its primary goal, showing a statistically significant rise in participants achieving EASI-75
Subscribe To Our Newsletter & Stay Updated